Orai3-Mediates Cisplatin-Resistance in Non-Small Cell Lung Cancer Cells by Enriching Cancer Stem Cell Population through PI3K/AKT Pathway

SIMPLE SUMMARY: Lung cancer is recognized for having a very poor prognosis with an overall survival rate of 5-years not exceeding 15%. Platinum-doublet therapy is the most current chemotherapeutic treatment used to treat lung tumors. However, resistance to such drugs evolves rapidly in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Daya, Hiba Abou, Kouba, Sana, Ouled-Haddou, Hakim, Benzerdjeb, Nazim, Telliez, Marie-Sophie, Dayen, Charles, Sevestre, Henri, Garçon, Loïc, Hague, Frédéric, Ouadid-Ahidouch, Halima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150283/
https://www.ncbi.nlm.nih.gov/pubmed/34065942
http://dx.doi.org/10.3390/cancers13102314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8150283/
https://www.ncbi.nlm.nih.gov/pubmed/34065942
http://dx.doi.org/10.3390/cancers13102314

Ejemplares similares